Ifabotuzumab

Drug Overview

Ifabotuzumab, also known as KB004, is a first-in-class investigational Targeted Therapy monoclonal antibody developed through a pioneering collaboration between Australian scientists at the Olivia Newton-John Cancer Research Institute, QIMR Berghofer, and Monash University, subsequently partnered with US biopharmaceutical company Humanigen. Ifabotuzumab is a non-fucosylated IgG1κ humanized antibody targeting the EphA3 receptor — a protein found abundantly on cancer cells and tumor blood vessels, but largely absent from healthy adult tissues.

What makes ifabotuzumab scientifically significant is its dual attack strategy: it targets cancer cells directly AND dismantles the blood vessel network that feeds the tumor — making it a uniquely positioned agent in both solid tumor and blood cancer treatment.

• Generic Name: Ifabotuzumab (KB004)
• US Brand Name: None assigned — currently investigational
• Drug Class: Anti-EphA3 Monoclonal Antibody / Receptor Tyrosine Kinase Inhibitor / Targeted Therapy
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Not FDA-approved. Ifabotuzumab has been explored in clinical trials aimed to treat refractory hematologic malignancies (NCT01211691) and is currently under active investigation in recurrent glioblastoma (NCT03374943). It holds the distinction of being the first EphA3-targeting drug for glioblastoma ever to enter clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand ifabotuzumab, it helps to know the role of EphA3 in cancer. EphA3 (Ephrin receptor A3) is a receptor tyrosine kinase — a cell-surface protein that, when overactivated in cancer, drives abnormal cell growth, promotes tumor blood vessel formation, and helps cancer cells evade the immune system. EphA3 is overexpressed and/or mutated in multiple tumors and is associated with poor prognosis and decreased survival in patients.

Ifabotuzumab attacks EphA3-expressing cancers through three interconnected mechanisms:

Direct Cancer Cell Targeting: Ifabotuzumab binds with high specificity to EphA3 on the surface of cancer cells. The antibody IIIA4 triggers rapid EphA3 activation and internalization by inducing a conformational change allowing for the assembly of EphA3/ephrin-A5 signal clusters. This internalization pulls the drug directly into the cancer cell, disrupting EphA3 signaling and triggering cancer cell death through antibody-dependent cellular cytotoxicity (ADCC) — a process where immune cells are recruited to destroy the antibody-tagged cancer cell.

Enhanced ADCC via Non-Fucosylation: Ifabotuzumab is deliberately engineered as a non-fucosylated antibody — meaning a specific sugar molecule (fucose) is removed from its structure. This modification dramatically enhances its ability to recruit natural killer (NK) cells via FcγRIIIa receptors, amplifying ADCC activity and making it a significantly more potent immune-activating agent than standard IgG1 antibodies.

Tumor Vasculature Disruption: EphA3 is a tumor-restricted antigen expressed in 38–40% of GBM and 100% of the tumor vasculature. By targeting EphA3 on tumor blood vessels, ifabotuzumab disrupts the vascular supply that feeds the tumor — cutting off its oxygen and nutrient delivery. MRI scans showed predominant T2/FLAIR changes, occasionally marked, which were consistent with treatment effect of ifabotuzumab on tumor vasculature, providing direct in-patient imaging evidence of this anti-vascular mechanism.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not FDA-Approved):

• Recurrent Glioblastoma Multiforme (GBM) — Phase I dose escalation and biodistribution study (NCT03374943) at the Olivia Newton-John Cancer Research Institute and Royal Brisbane and Women’s Hospital
• Relapsed or Refractory Hematologic Malignancies — including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other EphA3-expressing blood cancers (NCT01211691)
• EphA3 plays a role in hematologic disorders, gastric cancer, glioblastoma multiforme, colorectal cancer, lung cancer, renal cell carcinoma, and prostate cancer — representing a broad future development pipeline

Non-Oncological Uses:

• There are currently no non-oncological indications under formal clinical investigation for ifabotuzumab.

Dosage and Administration Protocols

On Day 8, patients commenced weekly ifabotuzumab infusions over 2 hours in one of three cohorts planned (3.5 mg/kg, 5.25 mg/kg, 7.9 mg/kg). In the GBM trial, a unique imaging-guided dosing approach is used, where a radiolabeled tracer dose is given first to confirm tumor targeting before therapeutic dosing begins.

Clinical Efficacy and Research Results

Ifabotuzumab has generated compelling evidence of precise tumor targeting and meaningful clinical activity across two distinct cancer populations.

In the Phase I hematologic malignancies trial (NCT01211691), published in Leukemia Research in 2016, ifabotuzumab demonstrated an acceptable safety profile with clinical activity in EphA3-expressing blood cancers — establishing the pharmacokinetic and pharmacodynamic foundation for its GBM development program. The trial confirmed that EphA3 is a druggable target in hematologic malignancies and that ifabotuzumab’s non-fucosylated design produced enhanced immune activation compared to standard antibodies.

In the Phase I GBM trial (NCT03374943), 12 patients were enrolled, including 6 in the 3.5 mg/kg and 6 in the 5.25 mg/kg dose cohorts. Treatment emergent adverse events included infusion reactions in 4 patients, seizures in 3 patients, cerebral edema in 1, rash in 1, headaches in 8, and eye disorder in 1. The best response was stable disease for 23 weeks. Critically, the imaging data confirmed that ifabotuzumab achieved what few drugs targeting GBM have ever demonstrated: ⁸⁹Zr-ifab-PET scans showed rapid, tumor-specific targeting at all known tumor sites and in all patients, but with no normal tissue uptake. This tumor-selective targeting with zero healthy brain tissue uptake is a landmark finding for a CNS oncology drug. Additional studies are planned to evaluate ifabotuzumab as part of an antibody-drug conjugate in various solid tumor types.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for ifabotuzumab, as it is not FDA-approved. Phase I clinical trials in patients with leukemia and brain cancer targeting EphA3 using monoclonal antibody KB004 demonstrate its safety and tolerability, with minimal adverse events reported.

Common Side Effects (>10%):

• Headache — the most frequently reported adverse event in the GBM trial, occurring in 8 of 12 patients; typically grade 1–2; managed with standard analgesics
• Infusion-Related Reactions — flushing, chills, or low-grade fever during infusion; seizures and infusion reactions were readily managed with increased premedications after the first occurrence
• Fatigue — mild and consistent with other IV oncology agents in this class

Serious Adverse Events:

• Seizures: Reported in 3 of 12 GBM patients; 2 were considered unrelated to study drug and likely related to underlying disease; managed with antiepileptic premedication adjustments
• Cerebral Edema: Reported in 1 patient; consistent with the drug’s tumor vasculature-modulating mechanism; monitored via MRI and managed with corticosteroids
• Embryo-Fetal Toxicity: Theoretical risk based on the mechanism of antibody-dependent immune activation; effective contraception required for all patients of reproductive potential

Management Strategies:

• For infusion reactions: reduce infusion rate; premedicate with diphenhydramine and corticosteroids before subsequent infusions
• For seizures: initiate or optimize antiepileptic therapy; perform urgent neurological assessment to distinguish drug effect from disease progression
• For cerebral edema: initiate corticosteroids (dexamethasone); perform urgent MRI to assess severity and extent

Research Areas

Ifabotuzumab’s development is actively evolving beyond its current monotherapy program. EphA3 emerges as a compelling candidate for CAR T-cell therapy based on its tumor-restricted expression pattern, and preclinical research published in 2024 demonstrated that EphA3-targeted CAR-T cells were highly effective against patient-derived glioblastoma neurospheres and organoids — directly building on the targeting validation established by the ifabotuzumab clinical program. Additionally, additional studies are planned to evaluate ifabotuzumab as part of an antibody-drug conjugate (ADC) in various solid tumor types — a development strategy that would arm the precision-targeting antibody with a cytotoxic payload, potentially transforming its therapeutic potency across multiple EphA3-expressing cancers.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• EphA3 expression testing of archival tumor tissue — mandatory for trial eligibility confirmation
• MRI brain with contrast — baseline tumor burden assessment and RANO criteria staging
• Complete blood count (CBC) with differential and comprehensive metabolic panel
• Baseline neurological assessment and seizure history review
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• ⁸⁹Zr-ifabotuzumab PET/CT imaging must be completed on Day 1 before therapeutic dosing begins on Day 8
• Antiepileptic premedication must be optimized before each weekly infusion in GBM patients
• MRI monitoring is required at regular intervals to distinguish treatment effect from disease progression

Do’s and Don’ts:

• DO inform your care team of any history of seizures before starting treatment — antiepileptic medications may need to be adjusted
• DO report any new or worsening headache, vision changes, or confusion immediately after infusion
• DO attend all scheduled PET/CT and MRI imaging appointments — they are essential for both safety and dosing decisions
• DON’T take ifabotuzumab outside of an approved and supervised clinical trial program
• DON’T miss any weekly infusion appointments — consistent dosing is critical for evaluating efficacy and safety
• DON’T become pregnant during treatment — the immune-activating mechanism carries a theoretical fetal harm risk

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Ifabotuzumab (KB004) is an investigational drug that is not approved by the US Food and Drug Administration (FDA) or any major regulatory authority for routine clinical use. It is currently available only through participation in approved clinical trials. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.